Xilio Therapeutics granted non-qualified stock options covering 100,895 common shares to two new employees and 105,000 shares to newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D. The grants were effective October 1, 2026, under the company’s Third Amended and Restated 2022 Inducement Stock Incentive Plan. The options have an exercise price of $8.91 per share, matching Xilio’s October 1 closing price, and expire after 10 years. Vesting begins with 25% on the first anniversary of each employee’s start date, followed by 36 equal monthly installments for the remaining 75%, subject to continued service. The awards were made as employment inducements under Nasdaq Listing Rule 5635(c)(4). Xilio is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to concentrate anti-tumor activity in the tumor microenvironment while reducing systemic side effects.